Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma

Head Neck. 2013 Dec;35(12):1796-800. doi: 10.1002/hed.23245. Epub 2013 Mar 6.

Abstract

Background: Over the past decade, intensity-modulated radiation therapy (IMRT) has gained widespread use in the treatment of head and neck cancer.

Methods: All patients with squamous cell carcinoma of the oropharynx treated with primary IMRT with or without chemotherapy over a 5-year period were reviewed. Outcomes and morbidity were analyzed and compared with previously published data.

Results: In all, 170 patients were included in the analysis. The 3-year local control, locoregional control, disease-free survival, and overall survival rates were 92%, 91%, 80%, and 87%, respectively. Feeding tubes were present in 55% of patients during treatment, but remained in only 1% 2 years following treatment.

Conclusions: This study confirms that IMRT yields excellent treatment outcomes for oropharyngeal carcinoma. Although acute toxicity remains a problem, late toxicity rates are low and long-term feeding tube dependence is rare compared with conventional radiation therapy.

Keywords: disease control; head and neck cancer; intensity-modulated radiation therapy; oropharyngeal carcinoma; treatment toxicity.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Carboplatin / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / mortality*
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / radiotherapy*
  • Cetuximab
  • Chemotherapy, Adjuvant
  • Cisplatin / therapeutic use
  • Disease-Free Survival
  • Enteral Nutrition
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Oropharyngeal Neoplasms / drug therapy
  • Oropharyngeal Neoplasms / mortality*
  • Oropharyngeal Neoplasms / pathology
  • Oropharyngeal Neoplasms / radiotherapy*
  • Radiotherapy Planning, Computer-Assisted
  • Radiotherapy, Intensity-Modulated* / adverse effects
  • Retrospective Studies

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Carboplatin
  • Cetuximab
  • Cisplatin